Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Kaźmierczak, Maciej ^a   Luczak, Magdalena ^b   Lewandowski, Krzysztof ^a   Handschuh, Luiza ^a,b   Czyż, Anna ^a   Jarmuż, Małgorzata ^a   Gniot, Michał ^a   Michalak, Michał ^a   Figlerowicz, Marek ^b,c   Komarnicki, Mieczysław ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Acute myeloid leukemia; Esterase D; Gamma 1 actin; Mass spectrometry; Outcome prognosis; Proteome profiling

Indexed keywords

ACTIN; CARBOXYLESTERASE; CATALASE; CYTARABINE; DOXORUBICIN; FLUDARABINE; GAMMA 1 ACTIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE OMEGA; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOCORTIN 1; PEROXIREDOXIN 6; PROTEOME; UNCLASSIFIED DRUG; ESD PROTEIN, HUMAN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER PROGNOSIS; CANCER REGRESSION; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT; BONE MARROW; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; NORMAL HUMAN; PATHOLOGY; PROGNOSIS; REMISSION; TUMOR RECURRENCE;

ACTINS; ADULT; AGED; BONE MARROW; CARBOXYLESTERASE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEOMICS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891881398     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0725-2     Document Type: Article

References (30)

1. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198-208.
2. Lockhart DJ, Winzeler EA. Genomic, gene expression and DNA arrays. Nature. 2000;405:827-36. (Pubitemid 30407861)
3. Valk PJ, Delwel R, Lowenberg B. Gene expression profiling in acute myeloid leukemia. Curr Opin Hematol. 2005;12:76-81. (Pubitemid 40189242)
4. Bullinger L, Dohner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, Döhner H, Pollack JR. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605-16. (Pubitemid 38501163)
5. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108:685-96. (Pubitemid 44061371)
6. Hanash SM, Neel JV, Baier LJ, Rosenblum BB, Niezgoda W, Markel D. Genetic analysis of thirty-three platelet polypeptides detected in two-dimensional polyacrylamide gels. Am J Hum Genet. 1986;38:352-60. (Pubitemid 16022082)
7. Balkhi MY, Trivedi AK, Geletu M, Christopeit M, Bohlander SK, Behre HM, Behre G. Proteomics of acute myeloid leukemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene. 2006;25:7041-58. (Pubitemid 44722072)
8. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154-64.
9. Luczak M, KaZmierczak M, Handschuh L, Lewandowski K, Komarnicki M, Figlerowicz M. Comparative proteome analysis of acute myeloid leukemia with and without maturation. J Proteomics. 2012;75:5734-48.
10. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:3453-74.
11. Shaffer LG, Slovak ML, Campbell LJ. An international system for human cytogenetic nomenclature. Basel: Karger; 2009.
12. Luczak M, KaZmierczak M, Handschuh L, Lewandowski K, Komarnicki M, Figlerowicz M. Comparative proteomics in acute myeloid leukemia. Contemp Oncol. 2012;16:95-103.
13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.
14. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Mullner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G. Approaching clinical proteomics: current state and future fields of application in cellular proteomics. Cytometry. 2009;75A:816-32.
15. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Mullner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med. 2009;47:724-44.
16. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Gruneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wormann B, Hiddemann W. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27:61-9.
17. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-65.
18. Roboz GJ. Novel approaches to the treatment of acute Myeloid Leukemia. Hematology. 2011;2011:43-50.
19. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107:69-79. (Pubitemid 29500811)
20. Gonzalez CF, Proudfoot M, Brown G, Korniyenko Y, Mori H, Savchenko AV, Yakunin AF. Molecular basis of formaldehyde detoxification. Characterization of two S-formylglutathione hydrolases from Escherichia coli, FrmB and YeiG. J Biol Chem. 2006;281:14514-22. (Pubitemid 43848382)
21. Wiedl T, Arni S, Roschitzki B, Grossmann J, Collaud S, Soltermann A, Hillinger S, Aebersold R, Weder W. Activity-based proteomics: Identification of ABHD11 and ESD activities as potential biomarkers for human lung adenocarcinoma. J Proteomics. 2011;74:1884-94.
22. Rubenstein PA. The functional importance of multiple actin isoforms. BioEssays. 1990;12:309-15. (Pubitemid 120034469)
23. Shum MSY, Pasquier E, Po'uha ST, O'Neill GM, Chaponnier C, Gunning PW, Kavallaris M. γ-Actin regulates cell migration and modulates the ROCK signaling pathway. FASEB J. 2011;25:4423-33.
24. Chen YR, Tan TH. The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol. 2000;16:651-62.
25. Potin S, Bertoglio J, Breard J. Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Lett. 2007;581:118-24. (Pubitemid 44960294)
26. Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MS. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients who are at least 65 years old. Leukemia Res. 2004;28:909-19. (Pubitemid 38960752)
27. Roboz GJ, Ritchie EK, Curcio T, Provenzano J, Carlin R, Samuel M, Wittenberg B, Mazumdar M, Christos PJ, Mathew S, Allen-Bard S, Feldman EJ. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer. 2008;113:2504-11.
28. Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin M-F, Cahalin P, Craig J, Bowen D, Russell N. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML dose not improve outcome. Leukemia. 2011;25:1122-7.
29. Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged < 60 years with acute myeloid leukemia. Cancer. 2011;117:4861-8.
30. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfii PP. PML targeting eradicates quiescent leukemia-initiating cells. Nature. 2008;453:1072-8. (Pubitemid 351871736)